Strategic expansion Vetter is rapidly expanding its manufacturing footprint with a 50,000 sqm production site and related facilities, signaling growing capacity needs and potential for long-term CDMO partnerships in scalable aseptic fill-finish capabilities.

Cold-chain leadership Recent launch of a mobile freezer solution highlights a focus on internal cold chain optimization, presenting cross-sell opportunities for temperature-controlled logistics, validated transport, and packaging services for temperature-sensitive biologics.

Financial strength Refinancing activity and recognition as a Best Managed Company reinforce robust financial health, enabling Vetter to commit to large-scale production investments and multi-year manufacturing programs, favorable for securing long-term contracts.

Strategic partnerships MoonLake Immunotherapeutics agreement demonstrates Vetter’s role as a trusted CMDO for partnership-heavy pipelines, indicating potential to pursue collaborations with other biotech firms developing complex biologics and oncology therapies.

Global supply readiness Global production sites in Europe and the United States, coupled with a family-led, sustainable operations culture, position Vetter as a reliable partner for global supply continuity, especially for cancer and multiple sclerosis therapies requiring compliant, scalable aseptic manufacturing.